CN Bio, a provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, has announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry.
Anton Vierietin Shutterstock
Under the agreement, Pharmaron will validate CN Bio’s PhysioMimix technology across existing applications and collaborate on integrating OOC technologies into its R&D platform. The partnership will also explore the development of new applications to address unmet needs in drug discovery and development.
The initial phase of the collaboration will focus on validating CN Bio’s PhysioMimix technology for current applications in disease modelling, toxicity testing and absorption, distribution, metabolism and excretion (ADME) studies. Following successful validation, the companies will work together to adopt the platform in priority R&D areas and co-develop novel applications to expand the capabilities of OOC technologies.
Pharmaron is a global drug R&D service platform, providing end-to-end services across drug discovery, preclinical, and clinical development. Through the partnership, CN Bio will install PhysioMimix instruments at Pharmaron’s facilities across the globe, enabling the joint development of OOC solutions tailored to evolving R&D challenges.
Dr Paul Brooks, CEO, CN Bio, said: “Pharmaron is a global, premier and trusted service provider for the life sciences industry. As such, Pharmaron were the ideal partner for CN Bio as we look to accelerate the growth of our OOC solutions portfolio in new and existing application areas. By working closely together and leveraging the industry-leading expertise of each company, we can share resources that enable us to progress new, innovative solutions from concept to global market deployment more effectively than ever before."